Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Comparative Hepatology|March 8, 2003
Advances in understanding the regulation of apoptosis and mitosis by peroxisome-proliferator activated receptors in pre-clinical models: relevance for human health and diseaseEric Boitier, Jean-Charles Gautier, Ruth Roberts
Environmental and Molecular Mutagenesis|June 15, 2007
Application of toxicogenomics to genetic toxicology risk assessmentVéronique Thybaud, Anne-Céline Le Fevre, Eric Boitier
Methods in Molecular Biology (Clifton, N.J.)|July 28, 2017
Next-Generation Sequencing to Investigate Urinary microRNAs from Macaca fascicularis (Cynomolgus Monkey)Yaligara Veeranagouda, Jean-François Léonard, Jean-Charles Gautier, et al.
Chemical Research in Toxicology|April 19, 2005
Characterization of an acute molecular marker of nongenotoxic rodent hepatocarcinogenesis by gene expression profiling in a long term clofibric acid studyCécile Michel, Ruth A Roberts, Chantal Desdouets, et al.
Mutation Research|March 22, 2007
Characterization of DNA reactive and non-DNA reactive anticancer drugs by gene expression profilingAnne-Celine Le Fevre, Eric Boitier, Jean-Pierre Marchandeau, et al.
Toxicology Letters|April 20, 2004
Regulation of apoptosis by peroxisome proliferatorsRuth A Roberts, Cecile Michel, Beth Coyle, et al.
The American Journal of Pathology|November 25, 2003
Liver gene expression profiles of rats treated with clofibric acid: comparison of whole liver and laser capture microdissected liverCécile Michel, Chantal Desdouets, Béatrice Sacre-Salem, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|July 3, 2007
Diethylnitrosamine initiation does not alter clofibric acid-induced hepatocarcinogenesis in the ratCecile Michel, Chantal Desdouets, Mohamed Slaoui, et al.
Toxicology and Applied Pharmacology|November 9, 2011
Integrated transcriptomic and proteomic evaluation of gentamicin nephrotoxicity in ratsEmmanuelle Com, Eric Boitier, Jean-Pierre Marchandeau, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 8, 2018
Lysophosphatidic Acid Receptor 1 Antagonist SAR100842 for Patients With Diffuse Cutaneous Systemic Sclerosis: A Double-Blind, Randomized, Eight-Week Placebo-Controlled Study Followed by a Sixteen-Week Open-Label Extension StudyYannick Allanore, Oliver Distler, Alexandre Jagerschmidt, et al.
Pageof 3